Latest news with #Non-alcoholicFattyLiverDisease
Business Upturn
11-08-2025
- Health
- Business Upturn
Shilpa Medicare shares jump 3% after CDSCO approval for NorUDCA tablets
By Aman Shukla Published on August 11, 2025, 09:19 IST Shilpa Medicare Limited shares surged by 3% in morning trade following a major announcement from the company. As of 9:18 AM, the shares were trading 3.83% higher at Rs 863.85. The Central Drugs Standard Control Organization (CDSCO) has granted approval for Shilpa Medicare's Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, indicated for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD). This approval is a significant milestone as it marks the first global authorization of NorUDCA for NAFLD treatment. NAFLD is a widespread liver condition, affecting approximately 25% of the global population, which translates to nearly 1.2 billion people worldwide. In India alone, around 188 million people are estimated to suffer from NAFLD. If left untreated, NAFLD can advance to non-alcoholic steatohepatitis (NASH), causing severe liver damage and complications. NorUDCA is recognized for its choleretic and anti-inflammatory effects, which help improve bile flow, reduce liver inflammation, and potentially slow the progression of liver diseases related to NAFLD. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
09-08-2025
- Health
- Business Upturn
Shilpa Medicare gets CDSCO approval for NorUDCA tablets 500 mg, marks first global clearance for NAFLD treatment
By Aman Shukla Published on August 9, 2025, 10:52 IST Shilpa Medicare Limited has announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO) for its Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD). According to the company, this is the first approval for NorUDCA for NAFLD anywhere in the world. NAFLD is one of the most common liver conditions globally, affecting about 25% of the world's population, which is roughly 1.2 billion people. In India, the estimated patient population is around 188 million. If not addressed in time, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and lead to serious liver complications. NorUDCA is described as having choleretic and anti-inflammatory properties, which can help improve bile flow, reduce inflammation in the liver, and potentially slow the progression of NAFLD and related liver disorders. Data from studies referenced by the company indicate that NorUDCA showed better results compared to placebo, with improvements in liver structure and function and no significant safety issues reported. The approval allows Shilpa Medicare to make NorUDCA available in India for NAFLD treatment. The company has stated that it aims to address an existing treatment gap for patients with this condition. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
